Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer buying?

Executive Summary

Aventis and Schering AG have entered into exclusive negotiations with Bayer to sell Aventis CropScience. Aventis holds a 76% interest and Schering owns 24%. Aventis would use the funds to pay down debt. Schering plans to put funds from the sale towards acquisitions or in-licensing arrangements

You may also be interested in...



Schering AG To Develop Leukine For Crohn’s Disease; Adds 200 Immunex Staff

Berlex plans to pursue a Crohn's disease indication for Leukine (sargramostim) following acquisition of the product from Immunex

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel